
Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC
Treatment with Braftovi (encorafenib) and Erbitux (cetuximab) plus chemotherapy demonstrated responses in patients with metastatic colorectal cancer with a BRAF V600E mutation, according to Dr. Cathy Eng, co-Director of GI Oncology; co-leader of the GI …